Indeed, the presence of high-frequency (and presumably tumor antigen-reactive) T-cell clones correlated with improved response in patients with prostate cancer treated with anti-CTLA-4 and a cancer vaccine18. This evidence concerns the gene CTLA4 and prostate cancer.